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Motor neuron loss is characteristic of many neurodegenerative disorders and results in rapid loss of muscle control, paralysis,and
eventual death in severe cases. In order to investigate the neurotrophic eﬀects of a motor neuron lineage graft, we transplanted
human embryonic stem cell-derived motor neuron progenitors (hMNPs) and examined their histopathological eﬀect in three
animal models of motor neuron loss. Speciﬁcally, we transplanted hMNPs into rodent models of SMA (Δ7SMN), ALS (SOD1
G93A), and spinal cord injury (SCI). The transplanted cells survived and diﬀerentiated in all models. In addition, we have also
found that hMNPs secrete physiologically active growth factors in vivo, including NGF and NT-3, which signiﬁcantly enhanced
the number of spared endogenous neurons in all three animal models. The ability to maintain dying motor neurons by delivering
motor neuron-speciﬁc neurotrophic support represents a powerful treatment strategy for diseases characterized by motor neuron
loss.
1.Introduction
Human embryonic stem cells (hESCs) can diﬀerentiate into
any cell type, are amenable to genetic manipulation, and
readily self-renew in vitro.D i r e c t e dd i ﬀerentiation of hESCs
into high purity populations of a deﬁned cell type can be
used to design eﬀective treatments that are both cell and
site speciﬁc. Stem cell-based transplantation is an inherently
combinatorial therapeutic approach, in that it not only
replaces dead or dying cells, but also provides a substrate
f o re n d o g e n o u sg r o w t h ,b r i d g e sg a p sw h e r et i s s u ei sl o s tt o
injury or disease, and provides neurotrophic support for the
endogenous environment.
Amyotrophic lateral sclerosis (ALS), spinal muscular
atrophy (SMA), and spinal cord injury (SCI) are all diseases
of motor neuron loss that could potentially beneﬁt from
transplantation of hESC-derived cells. ALS is the most
common form ofmotor neuron disease [1]a n dc a nb ee i t h e r
sporadic or familial [2–5]. Approximately 5–10% of those
diagnosed have a positive family history of the disease [1, 6].
Although the etiology of the sporadic form of ALS is largely
unknown [5], the familial form has a strong genetic linkage
to point mutations in either TAR DNA-binding protein 43
(TDP-43), FUS/TLS,o rt h eCu/Zn superoxide dismutase 1
(SOD1)genes[7].The averageageofonsetisbetween40and
60 years, and the disease is generally fatal within 1–5 years
of onset [1, 6]. SMA is also characterized by motor neuron
loss and is the leading genetic cause of infantile death [8, 9].
The disease manifests byroughly6monthsofageinthemost
severe cases (type I), and death follows in ∼2y e a r sw i t h o u t
supporting intervention [9, 10]. It is caused by a deletion
or mutation in the Survival Motor Neuron (SMN1)g e n e
[9, 11] in approximately 1 of every 10,000 live births [9, 10].
SCI involvesseveral degenerativeprocesses including butnot
limited to axonal and cellular damage to the motor neuron
compartment [12]. Each of these three neurodegenerative
diseases is characterized by the progressive loss of muscle
control and death of motor neurons within the spinal cord.2 Stem Cells International
Becausetheadultcentralnervoussystem(CNS)hasalimited
ability to repair itself, therapeutic strategies have focused
on ameliorating secondary cellular degeneration [12, 13],
promoting endogenous repair mechanisms [14–16], and cell
replacement [12, 17–19].
There is much evidence that transplantation of stem and
progenitor cells into the CNS produces functional improve-
ment even in the absence of functional integration. Human
neural stem cells constitutively secrete the neurotrophins
NGF, BDNF, and GDNF that promote growth of injured
axons following spinal cord injury [14, 20]. Atleast a portion
of the functional recovery seen after transplantation of
hESC-derived oligodendrocyte progenitor cells into models
of SCI has been attributed to secretion of growth factors
by the transplanted cells [12, 20–22]. This data indicates
that growth factors secreted by transplanted stem cells can
signiﬁcantly inﬂuence pathogenesis of the diseased/injured
spinal cord [20].
We have previously documented a method to diﬀerenti-
ate hESCsinto high purity populationsof human embryonic
stem cell-derived motor neuron progenitors (hMNPs) [20].
Inthisstudy,wesoughttoinvestigatewhetherhMNPssecrete
growth factors that have neurotrophic eﬀects on neurons
in culture and in three diﬀerent models of motor neuron
loss. We demonstrate that hMNPs secreted physiologically
active growth factors in vitro and in vivo and signiﬁcantly
enhanced the number of endogenous neurons following
transplantation in all three animal models of motor neuron
loss. From a therapeutic perspective, these observations
indicate that cell transplantation beneﬁts pathogenesis by
growth factor secretion, in addition to cell replacement.
2.Materialsand Methods
2.1. Ethics Statement. All animal work was carried out in
accordance with the UCI Institutional Animal Care and
Use Committee (2007-2725). Animals received appropriate
postsurgicalcareincludingsubcutaneoussaline,prophylactic
Baytril (2.5mg/kg/d, s.c.; Bayer, Shawnee Mission, KS),
and Buprenorphine (0.025mg/kg/d, s.c.; Western Medical
Supply, Los Angeles, CA) for three days. Animals were
inspected for weight loss, dehydration, discomfort, and
autophagia, with appropriate veterinary care as needed.
Research involving human participants was approved by the
UCI Institutional Review Board (2008-6467) and the UCI
Medical Center with written informed consent. All work
involving human embryonic stem cells was approved by the
UCI Human Embryonic Stem Cell Research and Oversight
Committee (2007-5645).
2.2. Derivation of hMNPs from hESCs. hMNPs were derived
from hESC lines hCSC14, hCSC14-CL1 (California Stem
Cell, Inc., Irvine, CA) at passages 15–17 and H7 at passages
26–38. hESCs were expanded on Matrigel (BD Biosciences,
San Jose, CA) for 1–3 weeks in StemBlast media (Cal-
ifornia Stem Cell, Inc., Irvine, CA) supplemented with
20ngbFGF/mL (Millipore, Billerica, MA). Cells were then
transferred to ultra low-binding dishes (Corning, NY) and
suspended in motor neuron (MN) diﬀerentiation media,
which consisted of osmolarity adapted DMEM:F12 mixture
(260mOsm) supplemented with Glutamax, B27 supplement
(Gibco-Invitrogen, Carlsbad, CA),insulin 10µg/mL, sodium
selenite 1ng/mL, transferrin 10µg/mL (Sigma Aldrich, St.
Louis, MO), MgSO4 0.5Mm, and bFGF 5ng/mL (Millipore,
Billerica, MA). Cells were exposed to this media for 5 days,
supplemented with 10µMr e t i n o i ca c i d( R A ;f r o m2 0 m M
stock solution in DMSO, Sigma-Aldrich, St. Louis, MO).
Cultures were fed daily for the duration of RA treatment,
then every 2 days for 16 subsequent days. At day 21,
cell clusters were transferred to adherent laminin substrate
(20µg/cm2). At day 28, the conditioned media was collected
for in vitro assays, or the cells were prepared for transplanta-
tion. Subsets of cells were plated onto laminin coated 4-well
c h a m b e rs l i d e s( N u n c ;F i s h e rS c i e n t i ﬁ c ,P i t t s b u r g h ,P A )f o r
immunocytochemical proﬁling.
2.3. Preparation of MN-Astrocyte Cocultures. To assess matu-
ration into a motor neuron phenotype, hMNPs were plated
onto primary astrocytes on day 28 and allowed to mature
for 3 weeks thereafter according to previously published
protocols [20] and Dr. John Weiss of UC, Irvine. Brieﬂy,
astrocyte cultures were prepared from cerebral cortices of
early postnatal (1–3 day) mice. After removing cortices,
the tissue was dissociated and plated at a density of about
2 × 104 cells/cm2, in media consisting of Eagle’s minimal
essential medium (MEM, Earle’s salts, supplied glutamine
free; serum; Gibco; Grand Island, NY), supplemented with
10% heat-inactivated horse serum (Gibco), 10% fetal bovine
serum (Gibco), glutamine (2mM; Gibco), glucose (total
25mM), and epidermal growth factor (ﬁnal concentration
10ng/mL) in 15mm Primaria-coated culture plates (Falcon;
Franklin Lake, NJ). Cultures were maintained in a 37◦C/5%
CO2 incubator. Under these conditions, there is virtually
no neuronal survival, the astrocyte monolayers generally
become conﬂuent after ∼2 weeks. After conﬂuence, the
astrocytemonolayerswereseededwithhMNPsatadensityof
50,000cells/cm2. Subsequently, media was exchanged twice
a week. Mature motor neurons were immunostained and
characterized as below.
2.4. Immunocytochemical Labeling. Immunocytochemistry
was performed using standard protocols, as described
previously [20]. The following proteins were evaluated:
anti-TUJ1 (1:1000), anti-HB9 (1:100; MNR2 Ab from
DSHB Developmental Studies Hybridoma Bank), anti-Islet1
(1:200),anti-GFAP(1:500)anti-SMI32(1:1000),andanti-
ChAT(1:100;Milliporeat4◦Covernight).Primary antibody
application was followed by ﬂuorescent secondary antibody
application (Alexaﬂuor-488 or -594 conjugated; Invitrogen,
Carlsbad, CA).
2.5. Primary Cortical Cultures. Mixed primary cortical
cultures were prepared from postnatal day 1 Sprague-
Dawley rats for neurite outgrowth with and without hMNP-
conditioned media (CM) or MN diﬀerentiation mediaStem Cells International 3
(without conditioning) as previously described in Rossi et
al. [20]. Brieﬂy, the cortex was mechanically dissociated,
trypsinized, and spun at 1500g for 5 minutes. The pellet
was resuspended in Neurobasal media (Invitrogen, Carlsbad,
CA). 40,000 cells were plated onto poly-L-lysine coated
chamber slides for neurite outgrowth [23]. After seeding, the
c h a m b e rs l i d e sw e r ef e df o rt h en e x t2d a y sw i t hN e u r o b a s a l
media supplemented with 10ng/mL FGF until neuronal
attachment.
2.6. In Vitro Growth Factor Secretion Assay. To determine
whether hMNP-conditioned media had neurotrophic eﬀects
on neurite outgrowth, MN diﬀerentiation media was condi-
tioned for 48 hours in the presence of hMNPs and removed
for presentation to cortical neurons. Primary cortical neu-
rons were fed with either MN diﬀerentiation media or
hMNP-CMdiluted1:1withMNdiﬀerentiationmedia (n =
4/group). MN diﬀerentiation media (without condition-
ing) consisted of osmolarity adapted DMEM:F12 mixture
(260mOsm) supplemented with Glutamax, B27 supple-
ment (Gibco-Invitrogen, Carlsbad, CA), insulin 10mg/mL,
sodium selenite 1ng/mL, transferrin 10mg/mL (Sigma
Aldrich, St. Louis, MO), MgSO4 0.5mM, and bFGF 5ng/ml
( M i l l i p o r e ,B i l l e r i c a ,M A )[ 20].
2.7. Transplantation of hMNPs ALS Model. The SOD1 G93A
mutant mice were supplied and bred for ALS-TDI by
GTC Biotherapeutics. Immune suppression was initiated
48 hours before procedures and consisted of a mixture of
FK506/Rapamycin, 1mg/kg of each. A laminectomy was
performed at lumbar level L2 across two vertebral bodies
at 60 days old. For transplantation, 32G Hamilton needles
with 30◦ bevels were used. A total of 40,000 hMNPs or CTS
(vehicle) were injected intraspinally. Each injection was a
total volume of 1µL, at a dose of 10,000cells/µL/injection.
Animals were survived to 110 days old.
Mice were divided into two groups of treated (transplan-
tation with hMNPs; n = 25) and vehicle control (vehicle-
injected; n = 25) groups that were evaluated up to the
end stage for protein expression and histological evaluation
of donor cell phenotype. Furthermore, 1 group of animals
(composed of 15 mice for both hMNP treated and vehicle
control SOD1 G93A mice) were analyzed for histological
quantiﬁcation and 1 group of animals were analyzed for
molecular analysis (composed of 10 mice for both hMNP
treated and vehicle control SOD1 G93A mice).
SMA Model. At postnatal day 1, Smn−/−;S M N Δ7+/+;
SMN2+/+ (hereafter referred to as Δ7SMN) pups were
cryoanesthetized, and a laminectomy was performed in the
upper lumber region. A glass-pulled tip attached to a Hamil-
tonsyringe was secured toastereotacticapparatusand atotal
of 20,000 hMNPs (10,000cell/uL) or volume equivalent of
vehicle was transplanted bilaterally into the spinal cord [24].
Miceweredividedintotreated(transplantationwithhMNPs;
n = 11) and vehicle control (vehicle-injected; n = 4) groups
that were evaluated up to the end stage for histological
analysis. Animals were survived up to 14 days old following
transplant.
SCI Model. Adult, female Sprague-Dawley rats (Charles
River Laboratories, San Diego, CA) were anesthetized using
Ketamine (100mg/kg) and Xylazine (10mg/kg, i.p.: West-
ern Medical Supply, Los Angeles, CA) and underwent a
T3 laminectomy. A 200kD bilateral contusion injury was
delivered using an Inﬁnite Horizons Impactor (Precision
Systems and Instruments, Lexington, KY). Animals received
a solution of 5mL ringers, 0.02mL Baytril, and 0.4mL
diluted buprenorphine subcutaneously 2 days postinjury.
Animals were also bladder expressed twice a day for min-
imum of 3 days, then as needed. Twenty-four hours prior
to transplantation, animals began daily immunosuppression
with cyclosporine A (20mg/kg/d, s.c.; Bedford Laboratories,
Bedford, OH). Animals also received antibiotic treatment of
Baytril (0.02mL) beginning one day prior to transplantation
and continued throughout post-op. Seven days after spinal
cord injury, animals received a transplantation of hMNPs;
following reexposure of the laminectomy site, the spinal
processofT2wasimmobilized,anda10µLHamiltonsyringe
(Hamilton, Reno, NV) with a 33G beveled needle was
lowered into the spinal cord using a stereotactic manipulator
arm. A totalof 100,000hMNPs or CTS(vehicle)was injected
in atotaloffour sites,2bilateralinjections cranialandcaudal
to the injury site (0.5mm lateral, 1.2mm deep) to target the
ventral horn. Each injection consisted of a total volume of
1µL, at a dose of 25,000cells/µL[ 20].
Mice were divided into two groups of treated (transplan-
tation with hMNPs; n = 30) and vehicle control (vehicle-
injected; n = 30) groups that were evaluated up to the end
stage for protein expression and histological evaluation of
donor cell phenotype. Furthermore, animals were split into
2 groups; the ﬁrst group was (composed of 20 mice for both
hMNP-treated and vehicle control SCI mice) analyzed for
histological quantiﬁcation and the second group of animals
was analyzed for molecular analysis (composed of n =
10 mice for both hMNP-treated and vehicle control SCI
mice). Animals were survived up to 3 months following
transplant.
2.8. Immunohistochemical Analyses of hMNPs. Animals were
sacriﬁced via transcardiac perfusion with 4% paraformalde-
hyde. The tissue was cryopreserved in 27% sucrose, and the
cords were sectioned into 1mm blocks and embedded in
OCT compound. Tissue was cryosectioned at 20µma n d
mounted onto gelatin-coated slides. Tissue sections were
blocked with 10% NDS in PBS and permeabilized with 0.1%
Triton X-100. To determine the fate of the transplanted
hMNPs, sections were processed for multiple markers.
Primary antibodies were added overnight at 4◦Cf o rK u 8 0
(1:300; Abcam), Islet-1 (1:200; Abcam), biotinylated NeuN
(1:200; Millipore), p75 (1:200, Santa Cruz Biotechnology,
Santa Cruz, CA), and ChAT (1:100; Millipore). Donkey
antirabbitconjugatedwith biotin(1:250;Invitrogen), Strep-
tavidin 594 (1:250; Invitrogen), Streptavidin 488 (1:250;
Invitrogen), or goat antirabbit Alexa Fluor-488/-594 (1:250;
Invitrogen) was used for 2 hours at room temperature as
secondary antibodies.4 Stem Cells International
2.9. Neuronal Sparing Analysis. The spinal cords from all
three animal models were analyzed for neuronal sparing.
Every tenth slide, spaced 200µm apart, was processed in
order to visualize the length of the spinal cord [20]. IHC
staining was performed on tissue slides using mouse anti-
NeuN (1:200; Millipore) primary antibodies to identify
neuronsand rabbitanti-Ku80(1:300;Abcam)primary anti-
bodies to identify human nuclei. Serial sections were labeled
with human nuclear antigen to ensure no human cells were
included in the analysis. For motor neuron sparing analysis,
mouse anti-ChAT (1:100; Millipore) primary antibodies
and rabbit anti-Ku80 (1:300; Abcam) primary antibodies
were used. The antibodies were diluted in PBS, incubated
o v e r n i g h ta t4 ◦C. Vector ABC Biotin Kit and Vectastain
DAB Substrate Kits were used for secondary detection.
Hoechst was used as a nuclear counterstain. Following IHC
staining, the tissue was imaged using an Olympus AX-80
microscope. Images were taken of transverse sections of
the ventral horns using MicroFire software. NeuN-positive
neurons were quantiﬁed up to 2mm cranial and 2mm
caudal to the injury epicenter or transplant site. The number
ofneurons was quantiﬁedusing ImageJ software. Each image
was openedindividuallyand changedtoan 8-bitimage. Each
image was then inverted, then the brightness and contrast
was adjusted to the Auto setting, which made the gray areas
darkerand neuronswere more easily visible. Then, threshold
was adjusted from Default to MaxEntropy setting. Finally,
the Nucleus Counter plug-in was used to detect pixels, the
smallest particle size set to 400 and largest particle size set
to 2000. Background subtraction and watershed ﬁlter were
used in the plug-in. The plug-in then showed the black and
white image of the neurons with a number indicating that
it was counted and a summary table of the total counts. If a
cell double stained positive for both NeuN and Ku80, then
that cell was not used in quantiﬁcation. Statistical analysis
was performed using a Student’s t-test (2 tailed distribution
and two sample equal variance).
2.10. ELISA. Transplanted spinal cords were analyzed for
growthfactorexpressionusing ELISA.Fresh epicenterblocks
were ﬂash frozen and then homogenized. Samples were
homogenized in ice cold T-Per Protein Extraction Reagent
(Pierce Biotechnology, Rockford, IL). Samples were kept at
−20◦C until analyzed with BCA protein assay. Triplicate
supernatant samples were used to determine total protein
levels present within the tissue using a BCA protein assay
kit (Pierce, Rockford, IL). Optical densities were read on
a THERMOmax ROM v1.72 plate reader at 450nm, and
the respective protein levels were quantiﬁed in comparison
to a bovine serum albumin (BSA) standard curve. The
ELISA kits used were NT-3 Emax Immuno Assay System
(Promega), NGF Emax ImmunoAssay System (Promega),
VEGF human ELISAkit(Invitrogen), NT-4 AccuBindELISA
kit (MonoBind, Inc.).
3.Results
3.1. In Vitro Diﬀerentiation. At day 28, the day of trans-
plantation, 93 ± 2.3% of cells expressed the neuronal axon
marker TUJ1 (Figure 1(a)), 96 ± 1.7% of the cells expressed
the motor neuron marker Islet-1 (Figure 1(b)), and 97 ±
2.6% of cells expressed the motor neuron marker HB9
(Figures 1(c) and 1(d)). Less than 1% of cells expressed the
astrocyte marker GFAP (Figure 1(a)) and no cells expressed
the mature motor neuron marker ChAT at day 28. No Oct4
positive stem cells could be identiﬁed on or after day 28 of
the diﬀerentiation protocol.
To assess maturation in vitro,h M N P sw e r ep l a t e d
on astrocytes and allowed to mature for a subsequent
3 weeks following day 28 of the diﬀerentiation protocol
(Figures 1(e) and 1(f)). Astrocytes did not immunostain
for the motor neuron markers SMI-32 (Figure 1(e))a n d
ChAT (Figure 1(f)), but were evident by hoescht staining.
Quantiﬁcation of astrocyte positive cells was therefore not
performed. The neuroﬁlament marker SMI-32 (Figure 1(e))
was expressed by 97.7 ± 1.53% of the cells and 96.6 ± 4.4%
ofthecellsexpressed thematuremotorneuronmarkerChAT
(Figure 1(f)); while HB9 expression decreased signiﬁcantly
(P< . 001; 6 ± 4.4%) from the day 28 diﬀerentiation
proﬁle. Motor neuron maturation was further demonstrated
bykainate-stimulateduptakeofCo2+ ionsbyCa2+ permeable
AMPA channels (not shown).
3.2. In Vivo Diﬀerentiation. Human nuclear (Ku80) antigen-
positive cells were detected in all transplanted animals of all
3 animal models and did not migrate from the transplant
sites cranial and caudal to the injection sites (Figure (2)).
Human cells (Figures 2(a) and 2(c)) double stained with
t h ey o u n gm o t o rn e u r o nm a r k e rI s l e t - 1( Figure 2(b))a n d
were observed in the ventral horns of hMNP treated but
not in vehicle control Δ7SMN animals. In Δ7SMN animals,
human nuclear antigen-positive cells did not double label
with markers forthe mature motorneuronmarkers ChAT or
SMI-32, indicating that their limited time in vivo (13 days)
is insuﬃcient for diﬀerentiation of transplanted hMNPs.
However, human cells were found within the SOD1 G93A
and SCI animals, in which animals were survived for up to
2 and 3 months, respectively, after transplantation. Human
cells were colabeled with neuronal and motor neuron
markers such as NeuN (Figure 2(d)), p75 (Figure 2(e))a n d
ChAT (Figure 2(f)), consistent with a motor neuron lineage
of a mixed maturation state. Many human nuclear antigen-
positive cells extended TUJ1-positive processes. TUJ1 tissue
staining was absent in no-primary and no-secondary anti-
body controls. Transplanted cells did not extend axons into
the periphery or form neuromuscular junctions with host
tissue, as expected.
3.3. In Vitro Growth Factor Secretion. Rossi et al [20]
have previously shown that hMNP’s secrete various growth
factors. To investigate the neurotrophic potential of hMNP
secretions, we performed functional assays of hMNP secre-
tions on cortical neurons in vitro (Figure 3). Neurite length
of cortical neuron cultures exposed to hMNP-conditioned
media (Figure 3(a)) was compared to neurite length of cor-
tical neuron cultures exposed to control MN diﬀerentiation
media only (without conditioning) (Figure 3(b))a n dw a sStem Cells International 5
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(f)
Figure 1: hMNP diﬀerentiation in vitro. At day 28, GFAP+ astrocytes ((a) red) were rare within TUJ1+ ((a) green) cultures. The majority
of TUJ1+ cells ((b, d) red) double stained for the motor neuron lineage marker Islet-1 ((b) green) and HB9 ((c, d) green). After 3 weeks of
subsequent growth,cells displayed amature, branched morphologyconsistentwithmature motorneurons,andexpressed the maturemotor
neuron markers SMI-32 ((e) green) and ChAT ((f) green). Counterstain in blue (a, d, e) and red (f). Bar = 50µm.
found to be signiﬁcantly greater (P<. 05; (Figure 3(c)).
Neuritelengthofcorticalneuronculturesexposed tohMNP-
conditioned media was 250µm ± 27µm, and neurite length
of cortical neuron cultures exposed to MN diﬀerentiation
media only was 151µm ± 32µm.
3.4. In Vivo GrowthFactor Secretion. The presence of growth
factors NGF, NT-3, VEGF, and NT-4, in the spinal cord of
animals was assessed in whole protein extracts via ELISA
(Figure 4). The levels of NGF protein were signiﬁcantly
greater (P<. 05) in hMNP-transplanted animals (76.3 ±
3.0pg/mL) as compared to vehicle control animals (68.1 ±
2.0pg/mL; Figure 4(a)). Similarly, the levels of NT-3 protein
were signiﬁcantly greater (P<. 05) in hMNP-transplanted
animals (66.5 ± 7.2pg/mL) as compared to vehicle control
animals (50.5 ± 3.1pg/mL; Figure 4(b)). There was no
signiﬁcant diﬀerence (P>. 05) in the level of VEGF
betweenthevehiclecontrol(387.8±13.3pg/mL)and hMNP
transplanted animals (382.9 ± 13.9pg/mL; Figure 4(c)).
Interestingly, NT-4 levels were signiﬁcantly greater (P<
.01) in the vehicle control animals (98.0 ± 4.5µg/mL), as
comparedtohMNP-transplanted animals (79.3±3.4µg/mL;
Figure 4(d)).
3.5. Neuronal Sparing. The average number of neurons in
the hMNP treated group and vehicle control group of all6 Stem Cells International
Ku80
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(f)
Figure 2: hMNP diﬀerentiation in vivo. Human nuclear (Ku80) antigen-positive cells were detected in all treated animals of all 3 animal
modelsandcolabeledwithdiﬀerentmotorneurondiﬀerentiationmarkers.Humannuclear(Ku80)antigen-positivecells(a,c)doublestained
with Islet-1 ((b) red), NeuN ((d) NeuN in red, human nuclei in green), p75 ((e) p75 in red, human nuclei in green), or ChAT ((f) ChAT in
blue, human nuclei in brown), consistent with a motor neuron lineage of mixed maturation state. Bar = 50µm.
3 animals was assessed for endogenous neuronal sparing
(Figure 5). In SCI and SOD1 G93A hMNP-treated animals
cranial to the injury/injection epicenter, there were 38 ± 3
and 43 ± 5 endogenous neurons counted, respectively. The
average number of neurons in the vehicle control group
of SCI and SOD1 G93A animals cranial to injury/injection
epicenter was 29 ± 2a n d2 7± 3, respectively. Cranial to the
injury/injection epicenter, the hMNP-treated group showed
a signiﬁcant sparing of neurons compared to the vehicle
control group in SCI (Figure 5(a); P<. 01) and SOD1
G93A animals (Figure 5(c); P<. 05). The average number of
neurons in the hMNP-treated group of SCI animals caudal
to the injury/injection epicenter was 36 ± 4. The average
number of neurons in the vehicle control group of SCI
animals caudal to the injury/injection epicenter was 37 ± 3.
The hMNP-treated group did not demonstrate statistical sig-
niﬁcance in neuronal sparing in SCI or SOD1 G93A animals
caudal to the injury/injection epicenter. Therefore, caudal
to the injury/injection epicenter, neuronal sparing was not
aﬀected by the transplantation of hMNPs, whereas hMNP
transplantation (Figure 5(e)) did spare neurons cranial to
the injury/injection epicenterand the vehicle control did not
(Figure 5(f)).
The average number of neurons in the hMNP treated
group in Δ7SMN animals cranial to the injection epicenter
was 304 ± 30. In the vehicle control group, the averageStem Cells International 7
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Figure 3: hMNPs cause neurite branching in vitro. Neurite length was signiﬁcantly longer (P<. 05) in cortical neuron cultures exposed to
hMNP-conditioned media (a) for 7 days as compared to cortical neuron cultures exposed to control MN diﬀerentiation media (b). (c) The
length of neurites in cultures exposed to hMNPconditioned media as compared to those exposed to control media was signiﬁcantly higher
(P<. 05). Bar = 50µm.
number of neurons cranial to injection epicenter was 304
± 46. Cranial to the injection epicenter, the hMNP-treated
group did not demonstrate a signiﬁcant sparing of neurons
compared to the control group (Figure 5(d)). The average
number of neurons in the hMNP-treated group in Δ7SMN
animals caudal to the injection epicenter was 386 ± 18.
However, average number of neurons in the vehicle control
group caudal to the injection epicenterwas 282 ± 29. Caudal
to the injection epicenter, the hMNP-treated group showed
statistical signiﬁcance in neuronal sparing (Figure 5(d); P<
.05). Therefore, cranial to the injection epicenter, neuronal
sparing was not aﬀected by the transplantation of hMNPs,
whereas hMNP transplantation did spare neurons caudal to
the injection epicenter.
3.6. Motor Neuron Sparing. The average number of ChAT
positive cells in the hMNP treated and vehicle control groups
was compared to examine whether neuronal sparing may
haveincludedendogenousmotorneurons(Figure 5(b)).The
average number of ChAT-positive cells within the ventral
horninSCIanimalsofthehMNP-transplanted groupcranial
to the injury/injection epicenter was 12 ± 2. The average
number of ChAT positive cells within the ventral horn
in SCI animals of the vehicle control group cranial to
the injury/injection epicenter was 7 ± 2. The number of
ChATpositivecellscranial totheinjury/injection epicenterin
the hMNP treated group was signiﬁcantly greater (P<. 05)
than that of the vehicle control group, demonstrating that
hMNP transplantation resulted also in the speciﬁc sparing
of endogenous motor neurons. There was no signiﬁcant
diﬀerence in the number of ChAT positive cells caudal to the
injury/injection epicenter, although there is a trend towards
increased sparing. The number of ChAT-positive cells caudal
to the injury/injection epicenter in the hMNP treated group
was 13 ± 2. The number of ChAT-positive cells caudal to the
injury/injection epicenter in the vehicle control group was 9
± 2.8 Stem Cells International
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Figure 4: hMNPs secrete physiologically active growth factors in vivo.E L I S Ad a t ao fN G F( a ) ,N T - 3( b ) ,V E G F( c ) ,a n dN T - 4( d )p r o t e i n
levels in the thoracic spinal cord transplanted region of SCI rats. Data is expressed as mean ± standard error. ∗P<. 05; ∗∗P<. 01. n = 6
hMNP; n = 9v e h i c l e .
4.Discussion
Transplantation is an inherently combinatorial therapeutic
approach, as it may provide neurotrophic support for the
endogenous environment, and cell phenotype-related ben-
eﬁts such as replacement of dead or dying cells, a substrate
for endogenous growth, or a tissue bridge for endogenous
growth. The relative contribution of neurotrophic support
and phenotypic beneﬁts conferred by a transplant is diﬃcult
or impossible to discern for transplants that consist of mixed
l i n e a g e s .I nt h i ss t u d y ,w ei n v e s t i g a t e dt h en e u r o t r o p h i c
eﬀects of a high purity motor neuron lineage graft in three
animal models of motor neuron loss. We demonstrate that
hMNPs secreted physiologically active growth factors in
vitro and in vivo and signiﬁcantly enhanced the number
of spared endogenous neurons following transplantation in
three animal models of motor neuron loss. The ability to
maintain dying motor neurons by delivering motor neuron-
speciﬁc neurotrophic support represents a powerful treat-
ment strategy for diseases characterized by motor neuron
loss.
Motorneurons respond toneurotrophiccuesand express
and secrete various growth factors [25]. Our data indicate
that hMNPs secrete NT-3, and NGF, and our previous
publicationfurtherindicatesthattheysecreteVEGFandNT-
4[20].NT-3andVEGFhaveknownbeneﬁcialeﬀectsonCNS
pathogenesis[16,26].Furthermore,ourinvitro datademon-
strate that hMNP-conditioned media enhanced elongation
and branching of cortical neurites, demonstrating that the
growth factor secretions from hMNPs were physiologically
relevant.
Our transplantation studies further conﬁrm that hMNPs
have physiologically relevant neurotrophic eﬀects in the
vicinity of the transplant. hMNP transplantation into SMA,
ALS, and SCI animal models resulted in beneﬁcial eﬀects
on injury pathogenesis, as evidenced by a greater num-
ber of spared endogenous neurons in all three animal
models. Although the growth factors secreted by hMNPs
in vivo have been implicated in neuronal survival [16,
26], the mechanisms underlying their interaction with the
endogenous environment are unknown. Their mechanism
of action may be direct, or indirect, as trophic supportStem Cells International 9
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of glial cells and/or modulation of the immune or glial
response may have contributed to survival of endogenous
neurons. Neurons within regions of pathology upregulate
p75 neurotrophin receptors (p75NTR) and downregulate
tyrosine-related kinase receptors (TrkRs) [16, 26]. The
p75NTRbindstheprecursorformsofneurotrophinsandhas
beenimplicatedinapoptosis, whileTrkRs bindmature forms
of neurotrophins and have been implicated in beneﬁcial
neurotrophic eﬀects [16, 26]. hMNP-secreted growth factors
may prevent, inhibit, or counteract neurotrophic action at
the p75NTR and/or enhance activation and/or upregulation
of TrkRs, enhancing downstream neurotrophic eﬀects.
This study directly assessed the potential of a cell-based
therapeutic to confer neurotrophic beneﬁt to regions of
pathogenesis in the absence of phenotypic beneﬁt. hMNP
transplants did not extend processes to reinnervate distant
muscles, so their neurotrophic beneﬁt to the diseased or
injured spinal cord could be investigated in isolation from
phenotypicbeneﬁtsconferredbyatransplant.These ﬁndings
further our understanding of the neurotrophic beneﬁts
of hMNP transplantation. Nonetheless, eﬀorts to mature
transplanted hMNPs andenhanceaxonalprojectiontotarget
muscles are important to maximize the beneﬁts of this cell
population.
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